Evidence map›Paper›PMID 14704037›Full record

ArticleInternational journal of hematology2003

MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.

Takayuki Tsujioka, Hideho Wada, Shunji Yamamori, Takemi Otsuki, Sinichiro Suemori, Toshinori Kondo, Hidekazu Nakanishi, Yoshimasa Suetsugu, Makoto Mikami, Takashi Sugihara

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Frontiers in pharmacology · 2023
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Takayuki TsujiokaDivision of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan. tsujoka@med.kawasaki-m.ac.jp
Hideho Wada
Shunji Yamamori
Takemi Otsuki
Sinichiro Suemori
Toshinori Kondo
Hidekazu Nakanishi
Yoshimasa Suetsugu
Makoto Mikami
Takashi Sugihara
Kawasaki Medical School · JPMitsubishi Group (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11)(p32;q23) translocation with confirmed MLL/AF-1p fusion. This case suggests that careful monitoring for MLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.

Indexed as

Translocation, GeneticAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsChromosomes, Human, Pair 1Chromosomes, Human, Pair 11CytarabineDaunorubicinEnzyme InhibitorsEtoposideFatal OutcomeHumansIdarubicinIn Situ Hybridization, FluorescenceLeukemia, Promyelocytic, AcuteMaleMiddle AgedAntineoplastic Agents, PhytogenicCytarabineDaunorubicinEnzyme InhibitorsEtoposideIdarubicinMitoxantroneMLL-AF-1p fusion protein, humanMyeloid-Lymphoid Leukemia ProteinNeoplasm ProteinsOncogene Proteins, FusionTopoisomerase II InhibitorsTretinoin

Identifiers

PMID14704037
OpenAlexW2033265409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.